CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer

Yung Taek Ouh, Hyun Woong Cho, Jae Kwan Lee, Song Hee Choi, Hyun Jin Choi, Jin-Hwa Hong

Research output: Contribution to journalArticle

Abstract

Objectives: Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. The oncogenic role of adiponectin is not known with regard to various cancer types. We sought to determine the role of adiponectin in angiogenesis in ovarian cancer in vitro. Methods: We transfected SKOV3 cells with vascular endothelial growth factor small interfering RNA in order to identify the independent angiogenic role of adiponectin in ovarian cancer. The vascular endothelial growth factor knockdown SKOV3 cell lines were treated with adiponectin for 48 h. The cytokines involved in adiponectin-mediated angiogenesis were explored using the human angiogenesis cytokine array and were verified with the enzyme-linked immunosorbent assay. The angiogenic effect of adiponectin was evaluated using the human umbilical vein endothelial cell tube formation assay. We also investigated the effects of adiponectin treatment on the migration and invasion of SKOV3 cells. Results: The number of tubes formed by human umbilical vein endothelial cell decreased significantly after knockdown of vascular endothelial growth factor (via transfection of vascular endothelial growth factor small interfering RNA into SKOV3 cells). When these vascular endothelial growth factor knockdown SKOV3 cells were treated with adiponectin, there was an increase in the number of tubes in a tube formation assay. Following adiponectin treatment, the CXC chemokine ligand 1 secretion increased in a cytokine array. This was confirmed by both enzyme-linked immunosorbent assay and Western blot. The increased secretion of CXC chemokine ligand 1 by adiponectin occurred regardless of vascular endothelial growth factor knockdown. In addition, the induction of migration and invasion of SKOV3 cells were significantly stronger with adiponectin treatment than they were without. Conclusion: Adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor. These findings suggest that adiponectin may serve as a novel therapeutic target for ovarian cancer.

Original languageEnglish
JournalTumor Biology
Volume42
Issue number4
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

CXC Chemokines
Adiponectin
Ovarian Neoplasms
Ligands
Vascular Endothelial Growth Factor A
Cytokines
Human Umbilical Vein Endothelial Cells
Small Interfering RNA
Obesity
Enzyme-Linked Immunosorbent Assay
Therapeutics
Adipokines

Keywords

  • Adiponectin
  • angiogenesis
  • CXC chemokine ligand 1
  • ovarian cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer. / Ouh, Yung Taek; Cho, Hyun Woong; Lee, Jae Kwan; Choi, Song Hee; Choi, Hyun Jin; Hong, Jin-Hwa.

In: Tumor Biology, Vol. 42, No. 4, 01.04.2019.

Research output: Contribution to journalArticle

Ouh, Yung Taek ; Cho, Hyun Woong ; Lee, Jae Kwan ; Choi, Song Hee ; Choi, Hyun Jin ; Hong, Jin-Hwa. / CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer. In: Tumor Biology. 2019 ; Vol. 42, No. 4.
@article{9400f0796fc04594828412b51c64d675,
title = "CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer",
abstract = "Objectives: Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. The oncogenic role of adiponectin is not known with regard to various cancer types. We sought to determine the role of adiponectin in angiogenesis in ovarian cancer in vitro. Methods: We transfected SKOV3 cells with vascular endothelial growth factor small interfering RNA in order to identify the independent angiogenic role of adiponectin in ovarian cancer. The vascular endothelial growth factor knockdown SKOV3 cell lines were treated with adiponectin for 48 h. The cytokines involved in adiponectin-mediated angiogenesis were explored using the human angiogenesis cytokine array and were verified with the enzyme-linked immunosorbent assay. The angiogenic effect of adiponectin was evaluated using the human umbilical vein endothelial cell tube formation assay. We also investigated the effects of adiponectin treatment on the migration and invasion of SKOV3 cells. Results: The number of tubes formed by human umbilical vein endothelial cell decreased significantly after knockdown of vascular endothelial growth factor (via transfection of vascular endothelial growth factor small interfering RNA into SKOV3 cells). When these vascular endothelial growth factor knockdown SKOV3 cells were treated with adiponectin, there was an increase in the number of tubes in a tube formation assay. Following adiponectin treatment, the CXC chemokine ligand 1 secretion increased in a cytokine array. This was confirmed by both enzyme-linked immunosorbent assay and Western blot. The increased secretion of CXC chemokine ligand 1 by adiponectin occurred regardless of vascular endothelial growth factor knockdown. In addition, the induction of migration and invasion of SKOV3 cells were significantly stronger with adiponectin treatment than they were without. Conclusion: Adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor. These findings suggest that adiponectin may serve as a novel therapeutic target for ovarian cancer.",
keywords = "Adiponectin, angiogenesis, CXC chemokine ligand 1, ovarian cancer",
author = "Ouh, {Yung Taek} and Cho, {Hyun Woong} and Lee, {Jae Kwan} and Choi, {Song Hee} and Choi, {Hyun Jin} and Jin-Hwa Hong",
year = "2019",
month = "4",
day = "1",
doi = "10.1177/1010428319842699",
language = "English",
volume = "42",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer

AU - Ouh, Yung Taek

AU - Cho, Hyun Woong

AU - Lee, Jae Kwan

AU - Choi, Song Hee

AU - Choi, Hyun Jin

AU - Hong, Jin-Hwa

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objectives: Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. The oncogenic role of adiponectin is not known with regard to various cancer types. We sought to determine the role of adiponectin in angiogenesis in ovarian cancer in vitro. Methods: We transfected SKOV3 cells with vascular endothelial growth factor small interfering RNA in order to identify the independent angiogenic role of adiponectin in ovarian cancer. The vascular endothelial growth factor knockdown SKOV3 cell lines were treated with adiponectin for 48 h. The cytokines involved in adiponectin-mediated angiogenesis were explored using the human angiogenesis cytokine array and were verified with the enzyme-linked immunosorbent assay. The angiogenic effect of adiponectin was evaluated using the human umbilical vein endothelial cell tube formation assay. We also investigated the effects of adiponectin treatment on the migration and invasion of SKOV3 cells. Results: The number of tubes formed by human umbilical vein endothelial cell decreased significantly after knockdown of vascular endothelial growth factor (via transfection of vascular endothelial growth factor small interfering RNA into SKOV3 cells). When these vascular endothelial growth factor knockdown SKOV3 cells were treated with adiponectin, there was an increase in the number of tubes in a tube formation assay. Following adiponectin treatment, the CXC chemokine ligand 1 secretion increased in a cytokine array. This was confirmed by both enzyme-linked immunosorbent assay and Western blot. The increased secretion of CXC chemokine ligand 1 by adiponectin occurred regardless of vascular endothelial growth factor knockdown. In addition, the induction of migration and invasion of SKOV3 cells were significantly stronger with adiponectin treatment than they were without. Conclusion: Adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor. These findings suggest that adiponectin may serve as a novel therapeutic target for ovarian cancer.

AB - Objectives: Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. The oncogenic role of adiponectin is not known with regard to various cancer types. We sought to determine the role of adiponectin in angiogenesis in ovarian cancer in vitro. Methods: We transfected SKOV3 cells with vascular endothelial growth factor small interfering RNA in order to identify the independent angiogenic role of adiponectin in ovarian cancer. The vascular endothelial growth factor knockdown SKOV3 cell lines were treated with adiponectin for 48 h. The cytokines involved in adiponectin-mediated angiogenesis were explored using the human angiogenesis cytokine array and were verified with the enzyme-linked immunosorbent assay. The angiogenic effect of adiponectin was evaluated using the human umbilical vein endothelial cell tube formation assay. We also investigated the effects of adiponectin treatment on the migration and invasion of SKOV3 cells. Results: The number of tubes formed by human umbilical vein endothelial cell decreased significantly after knockdown of vascular endothelial growth factor (via transfection of vascular endothelial growth factor small interfering RNA into SKOV3 cells). When these vascular endothelial growth factor knockdown SKOV3 cells were treated with adiponectin, there was an increase in the number of tubes in a tube formation assay. Following adiponectin treatment, the CXC chemokine ligand 1 secretion increased in a cytokine array. This was confirmed by both enzyme-linked immunosorbent assay and Western blot. The increased secretion of CXC chemokine ligand 1 by adiponectin occurred regardless of vascular endothelial growth factor knockdown. In addition, the induction of migration and invasion of SKOV3 cells were significantly stronger with adiponectin treatment than they were without. Conclusion: Adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor. These findings suggest that adiponectin may serve as a novel therapeutic target for ovarian cancer.

KW - Adiponectin

KW - angiogenesis

KW - CXC chemokine ligand 1

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85064193650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064193650&partnerID=8YFLogxK

U2 - 10.1177/1010428319842699

DO - 10.1177/1010428319842699

M3 - Article

C2 - 30967059

AN - SCOPUS:85064193650

VL - 42

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 4

ER -